Measuring Signs of Atopic Dermatitis in Clinical Practice
JAMA Dermatology · 01.08.2024 · 160 (8) · 878
DOI: 10.1001/jamadermatol.2024.1162 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Dermatology, erschienen am 01.08.2024. Verfasst von Michael E Jacobson und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Oregon Health & Science University, Portland. Hauptthemen laut MEDLINE: Consensus, Dermatitis, Atopic, Severity of Illness Index. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 55 Literaturangaben.
Abstract (Originalsprache)
Importance Outcome measurement is an essential component of value-based health care and can aid patient care, quality improvement, and clinical effectiveness evidence generation. The Harmonising Outcome Measures for Eczema Clinical Practice initiative aims to identify a list of validated, feasible, outcome measurement instruments recommended to measure atopic dermatitis (AD) in the clinical practice setting. The clinical practice set is a list of instruments that clinicians can pick and choose from to suit their needs in the context of clinical care.
Objective
To recommend instruments to measure clinical signs of AD in clinical practice. Evidence Review Following the predefined roadmap, a mixed methods design was implemented and incorporated systematic reviews and qualitative consensus methods. Previous systematic reviews identified few clinical signs instruments with sufficient validation for recommendation. An updated systematic review evaluating the validity of clinical signs instruments informed an international meeting to reach consensus on recommended instruments to measure AD clinical signs in clinical practice. Consensus was defined as less than 30% disagreement. An in-person consensus exercise was held in Montreal, Canada, on October 16, 2022. The 34 attendees included patient and patient advocate research partners, health care professionals, researchers, methodologists, and industry representatives.
Findings
The updated systematic review found that the Eczema Area and Severity Index (EASI), Scoring Atopic Dermatitis, and objective Scoring Atopic Dermatitis were the only instruments that demonstrated sufficient performance in all assessed measurement properties. The modified EASI and Signs Global Assessment × Body Surface Area instruments were also recommended. The EASI, Validated Investigator Global Assessment, and Investigator’s Global Assessment multiplied by or measured concurrently with a body surface area measure achieved consensus in criteria and were adopted. Conclusions and Relevance This consensus statement by the Harmonising Outcome Measures for Eczema initiative suggests that when assessing and documenting clinical signs of AD, there are several valid and feasible instruments that can best fit a clinician’s specific practice needs. These instruments should improve and standardize the documentation of signs severity, help determine the effect of treatment, facilitate the generation of clinical effectiveness evidence, and enhance the implementation of value-based health care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Dermatology, Oregon Health & Science University, Portland.
- Division of Dermatology, Rabin Medical Center, Petah Tikva, Israel.
- Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Institute of Social Medicine and Health Systems Research, Otto von Guericke University Magdeburg, Magdeburg, Germany.
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
- Department of Dermatology, Amsterdam UMC, Academic Medical Center, University of Amsterdam, Amsterdam Public Health, Infection and Immunity, Amsterdam, the Netherlands.
Zitieren
APA
Jacobson, M. E., Leshem, Y. A., Apfelbacher, C., Spuls, P. I., Gerbens, L. A. A., Thomas, K. S., Williams, H. C., Katoh, N., Howells, L., Schmitt, J., Deckert, S., Seshadri, R., Simpson, E. L., & Harmonising Outcome Measures for Eczema (HOME) initiative (2024). Measuring Signs of Atopic Dermatitis in Clinical Practice. JAMA Dermatology, 160(8), 878. https://doi.org/10.1001/jamadermatol.2024.1162
Vancouver
Jacobson ME, Leshem YA, Apfelbacher C, Spuls PI, Gerbens LAA, Thomas KS, et al. Measuring Signs of Atopic Dermatitis in Clinical Practice. JAMA Dermatology. 2024;160(8):878. doi:10.1001/jamadermatol.2024.1162
BibTeX
@article{Jacobson2024,
author = {Jacobson, Michael E and Leshem, Yael A and Apfelbacher, Christian and Spuls, Phyllis I and Gerbens, Louise A A and Thomas, Kim S and Williams, Hywel C and Katoh, Norito and Howells, Laura and Schmitt, Jochen and Deckert, Stefanie and Seshadri, Rishi and Simpson, Eric L and Harmonising Outcome Measures for Eczema (HOME) initiative, Harmonising Outcome Measures for Eczema (HOME) initiative},
title = {Measuring Signs of Atopic Dermatitis in Clinical Practice},
journal = {JAMA Dermatology},
year = {2024},
volume = {160},
number = {8},
pages = {878},
doi = {10.1001/jamadermatol.2024.1162}
}
EUVIMED